Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.
Pai M, Adhikari NKJ, Ostermann M, Heels-Ansdell D, Douketis JD, Skrobik Y, Qushmaq I, Meade M, Guyatt G, Geerts W, Walsh MW, Crowther MA, Friedrich JO, Burry L, Bellomo R, Brandão da Silva N, Costa Filho R, Cox MJ, Alves Silva S, Cook DJ; PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial) Investigators. Pai M, et al. Among authors: geerts w. PLoS One. 2018 Jun 1;13(6):e0198285. doi: 10.1371/journal.pone.0198285. eCollection 2018. PLoS One. 2018. PMID: 29856817 Free PMC article. Clinical Trial.
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group. Douketis J, et al. Among authors: geerts w. Arch Intern Med. 2008 Sep 8;168(16):1805-12. doi: 10.1001/archinte.168.16.1805. Arch Intern Med. 2008. PMID: 18779469 Clinical Trial.
Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes.
Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, Crowther M, Warkentin TE, Dodek P, Cade J, Lesur O, Lim W, Fowler R, Lamontagne F, Langevin S, Freitag A, Muscedere J, Friedrich JO, Geerts W, Burry L, Alhashemi J, Cook D; PROTECT collaborators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Williamson DR, et al. Among authors: geerts w. Chest. 2013 Oct;144(4):1207-1215. doi: 10.1378/chest.13-0121. Chest. 2013. PMID: 23788287 Clinical Trial.
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group. Fowler RA, et al. Among authors: geerts w. JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101. JAMA. 2014. PMID: 25362228
Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*.
Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, Dodek P, McIntyre L, Hall R, Heels-Ansdell D, Fowler R, Pai M, Guyatt G, Crowther MA, Warkentin TE, Devereaux PJ, Walter SD, Muscedere J, Herridge M, Turgeon AF, Geerts W, Finfer S, Jacka M, Berwanger O, Ostermann M, Qushmaq I, Friedrich JO, Cook DJ; PROphylaxis for ThromboEmbolism in Critical Care Trial Investigators. Lim W, et al. Among authors: geerts w. Crit Care Med. 2015 Feb;43(2):401-10. doi: 10.1097/CCM.0000000000000713. Crit Care Med. 2015. PMID: 25474533 Clinical Trial.
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.
Cook DJ, Rocker G, Meade M, Guyatt G, Geerts W, Anderson D, Skrobik Y, Hebert P, Albert M, Cooper J, Bates S, Caco C, Finfer S, Fowler R, Freitag A, Granton J, Jones G, Langevin S, Mehta S, Pagliarello G, Poirier G, Rabbat C, Schiff D, Griffith L, Crowther M; PROTECT Investigators; Canadian Critical Care Trials Group. Cook DJ, et al. Among authors: geerts w. J Crit Care. 2005 Dec;20(4):364-72. doi: 10.1016/j.jcrc.2005.09.010. J Crit Care. 2005. PMID: 16310609 Clinical Trial.
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M; Canadian Critical Care Trials Group. Cook D, et al. Among authors: geerts w. Crit Care. 2008;12(2):R32. doi: 10.1186/cc6810. Epub 2008 Mar 3. Crit Care. 2008. PMID: 18315876 Free PMC article.
220 results